
Merck and Daiichi Sankyo Launch Global Phase III Trial of Novel Antibody Drug Conjugate in Advanced Esophageal Squamous ...
Key Takeaways Phase III IDeate-Esophageal01 Trial Launches Merck and Daiichi Sankyo have initiated a global, multicenter Phase III trial evaluating ifinatamab deruxtecan (I-DXd) in patients with advanced or metastatic esophageal squamous cell carcinoma ( …